Literature DB >> 17034403

Medication overuse headache: biobehavioral issues and solutions.

Alvin E Lake1.   

Abstract

This article reviews current research on medication-overuse headache (MOH), and provides clinical suggestions for effective treatment programs. Epidemiological research has identified reliance on analgesics as a predictive factor in headache chronicity. MOH can be distinguished as simple (Type I) or complex (Type II). Simple cases involve relatively short-term drug overuse, relatively modest amounts of overused medications, minimal psychiatric contribution, and no history of relapse after drug withdrawal. In contrast, complex cases often present with multiple psychiatric comorbidities and a history of relapse. Although limited, current research suggests that comorbid psychiatric disorders are more prevalent in MOH than in control headache conditions, and may precede the onset of MOH. There appears to be an elevated risk of family history of substance use disorders in MOH patients, and an increased risk of MOH in patients with diagnosed personality disorders. Current studies suggest a high rate of relapse at 3 to 4 years after drug withdrawal and pharmacological treatment, with most relapse occurring during the first year of treatment. Relapse is a greater problem with analgesics than ergots or triptans. The addition of behavioral treatment to prophylactic medication may significantly reduce the risk of relapse over a period of several years. Clinical recommendations include assessment and modification of psychological factors that may underlie MOH, provision of detailed educational information, and combining behavioral treatment with the current standard of drug withdrawal and use of prophylactic pharmacotherapy.

Entities:  

Mesh:

Year:  2006        PMID: 17034403     DOI: 10.1111/j.1526-4610.2006.00560.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  30 in total

1.  One-day behavioral treatment for patients with comorbid depression and migraine: a pilot study.

Authors:  Lilian Dindo; Ana Recober; James N Marchman; Carolyn Turvey; Michael W O'Hara
Journal:  Behav Res Ther       Date:  2012-05-27

Review 2.  Non-pharmacological approaches to treating chronic migraine with medication overuse.

Authors:  F Andrasik; L Grazzi; S Usai; D C Buse; G Bussone
Journal:  Neurol Sci       Date:  2009-05       Impact factor: 3.307

Review 3.  Tension-type headache with medication overuse: pathophysiology and clinical implications.

Authors:  Teshamae S Monteith; Michael L Oshinsky
Journal:  Curr Pain Headache Rep       Date:  2009-12

Review 4.  Medication-overuse headache: epidemiology, diagnosis and treatment.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  Ther Adv Drug Saf       Date:  2014-04

Review 5.  Chronic headache: the role of the psychologist.

Authors:  Robert A Nicholson
Journal:  Curr Pain Headache Rep       Date:  2010-02

Review 6.  Medication overuse headache: awareness, detection and treatment.

Authors:  Alan M Rapoport
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism.

Authors:  Cherubino Di Lorenzo; Giorgio Di Lorenzo; Grazia Sances; Natascia Ghiotto; Elena Guaschino; Gaetano S Grieco; Filippo M Santorelli; Carlo Casali; Alfonso Troisi; Alberto Siracusano; Francesco Pierelli
Journal:  J Headache Pain       Date:  2009-06-11       Impact factor: 7.277

Review 8.  Headache secondary to psychiatric disorders.

Authors:  Todd A Smitherman; Steven M Baskin
Journal:  Curr Pain Headache Rep       Date:  2008-08

Review 9.  Behavioral medicine for migraine and medication overuse headache.

Authors:  Frank Andrasik; Dawn C Buse; Licia Grazzi
Journal:  Curr Pain Headache Rep       Date:  2009-06

10.  One-day behavioral intervention in depressed migraine patients: effects on headache.

Authors:  Lilian Dindo; Ana Recober; James Marchman; Michael W O'Hara; Carolyn Turvey
Journal:  Headache       Date:  2014-03       Impact factor: 5.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.